Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC) (MBC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The investigators want to know the role of Peripheral hematopoietic stem cell infusion in avoiding Drug Induced Liver Injury,and also try to research SNPs genotyping associated with Drug Induced Liver Injury.
Condition or disease
Breast NeoplasmsNeoplasm Metastasis
The researcher investigate the incidence and the cause of Drug Induced Liver Injury in MBC.
Patients having a complete clinical history and physical examination, receive routine chemotherapy.
Venous blood Sample(4 ml)is collected before and after each cycle according to the planning time.
Genomic DNA,RNA and upper serum is isolated. ELISA、rt-PCR or PCR-direct sequencing is used to detect the protein or gene expression associated with liver function.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
female patients with metastatic breast cancer
Patients should be histologically confirmed with metastatic breast cancer;
an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Normal cardiac, hepatic, renal and bone marrow functions;
Life expectancy ≥3 months;
previous history of other malignancies;
Central nervous system metastases;
Serious or uncontrolled concurrent medical illness.